对于已经接受了一线治疗但晚期黑色素瘤无效的患者来说，他们需要有有效的二线治疗选择。最近的一个3期临床试验表明，对于晚期黑色素瘤患者，采用肿瘤浸润淋巴细胞（TILs）的养育细胞治疗作为二线治疗显示出了有希望的结果。然而，患者及其伴侣对于TILs治疗的体验如何尚不为人知，这对于评估和改善照护质量至关重要。我们对晚期黑色素瘤患者及其伴侣进行了关于TILs治疗体验的半结构化访谈，分为治疗后2-4周（短期）和治疗后>6个月（长期）两个阶段。总共进行了25次访谈，其中包括接受TILs治疗的晚期黑色素瘤患者（n=13）及其伴侣（n=12），其中大部分为短期访谈（n=17）。总的来说，患者及其伴侣对于TILs治疗的体验是强烈的（成功养育TILs的不确定性，多种治疗相关的毒副作用和长时间住院）。在TILs治疗期间，有小孩或其他照护责任的患者及其伴侣面临的挑战最多。然而，所有患者都报告了除了疲劳之外的所有治疗相关毒副作用在2-4周内的恢复。临床数据支持TILs治疗在晚期黑色素瘤治疗中的作用。由于TILs治疗与当前常规治疗方式的明显不同，我们提出了以患者为中心的建议，以进一步提高TILs治疗的质量。随着未来更多晚期黑色素瘤患者预计将接受TILs治疗，我们的发现可以纳入这个新颖的TILs治疗组的治疗后生存计划中。© 2023. 作者（们），根据Springer Science+Business Media, LLC, part of Springer Nature的独家许可。

Patients with advanced melanoma refractory to first-line treatment have a need for effective second-line treatment options. A recent phase 3 trial showed promising results for adoptive cell therapy with tumor-infiltrating lymphocytes (TILs) as second-line therapy in patients with advanced melanoma. However, it remains unknown how patients and their partners experience TIL therapy, which is key to evaluate and improve the quality of care.Semi-structured interviews about the experience of TIL therapy were conducted with patients with advanced melanoma and their partners 2-4 weeks post-treatment (short term) and >6 months after treatment (long term).In total, 25 interviews were conducted with advanced melanoma patients treated with TIL (n=13) and their partners (n=12), with the majority being short-term interviews (n=17). Overall, patients and partners experienced TIL therapy as intense (uncertainty of successful TIL culture, multiple treatment-related toxicities, and extensive hospitalization). Patients and partners with young children or other caregiving responsibilities encountered the most challenges during TIL therapy. All patients, however, reported a recovery of all treatment-related toxicities within 2-4 weeks (except fatigue).Clinical data justify the role of TIL therapy in the treatment of advanced melanoma. With the distinct nature of TIL therapy compared to the current standard of care, we have provided patient-centered recommendations that will further enhance the quality of TIL therapy.As more patients with advanced melanoma are expected to receive TIL therapy in the future, our findings could be incorporated into survivorship care plans for this novel group of advanced melanoma survivors treated with TIL.© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.